View All

Using In-country Comparables to Measure the Returns Due Pharmaceutical Marketing and Distribution Affiliates	Published Article 2003-12-01	By Dr. Richard Rozek et al.
Investment Incentives Created by the Montreal Protocol and FDA Policy on Albuterol	Published Article 2003-11-20	By Dr. Richard Rozek et al.
The Impact on Patients and Payers of Designating Albuterol a Non-Essential Use of an Ozone Depleting Substance	Regulatory Filing 2003-09-09	By Dr. Richard Rozek with former NERA Consultant Emily Bishko Radel
Are Mergers the Right Medicine for Japan's Pharmaceutical Industry?	Presentation 2002-10-20	By Dr. Richard Rapp
Broad-Based Compulsory Licensing of Pharmaceutical Technologies: Unsound Public Policy	Published Article 2001-07-01	By Dr. Richard Rozek et al.
Reimbursing Generics in the UK: Is There a Better Way?	Published Article 2001-03-01	By NERA Special Advisor Ian Senior
The WTO Dispute Settlement Mechanism: TRIPS Rulings and the Developing Countries: Prospects After Seattle	Published Article 2001-03-01	By Dr. Richard Rozek
The Effects of Compulsory Licensing on Innovation and Access to Health Care	Published Article 2000-11-01	By Dr. Richard Rozek
A Comparables Approach To Measuring Cash-Flow-At-Risk (c-far) For Non-Financial Firms	Working Paper 2000-08-01	By Louis Guth and Dr. Michael Tennican, et al.
Valuing Trademarks: The Devil in the Details	Published Article 2000-04-01	By Dr. Phillip Beutel
< Back 1 2 3 Next >

NERA Economic Consulting